Tablets 100mg, 300mg
27/10/22 - Dapagliflozin 10mg film-coated tablets added for SMC 2428 for the treatment of chronic kidney disease.
The choice of SGLT2 inhibitor therapy depends on the indication for prescribing see: SGLT2 inhibitor guidance.
Note: There have been reports of atypical diabetic ketoacidosis (DKA) with the use of SGLT2 inhibitors. Although extremely rare, atypical DKA has been reported in patients with type 1 and type 2 diabetes at blood sugar levels not normally associated with DKA, ie 14mmol/L. There is no need to withdraw the SGLT2 inhibitor but specialist advice is as follows:
MHRA advice: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness (March 2020) (www.gov.uk).
MHRA advice: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (February 2019) (www.gov.uk).
MHRA advice: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) (March 2017) (www.gov.uk).
Tablets 5mg, 10mg
As per SMC 2428 for the treatment of chronic kidney disease (for this indication it is specialist initiation or recommendation only).